Stock Price
5.94
Daily Change
-0.01 -0.17%
Monthly
-9.04%
Yearly
68.27%
Q1 Forecast
5.72



Peers Price Chg Day Year Date
Cspc Pharmaceutical 8.67 0.08 0.93% 79.50% Mar/16
Sino Biopharmaceutical 5.94 -0.01 -0.17% 68.27% Mar/16
Avita Medical 1.25 -0.02 -1.34% -53.78% Mar/16
Jiangsu Hengrui 55.11 -0.19 -0.34% 18.41% Mar/13
Akebia Therapeutics 1.46 0.06 4.29% -35.40% Mar/13
Tectonic Therapeutic 33.31 -0.81 -2.37% 29.96% Mar/13
Ionis Pharmaceuticals 71.19 -1.15 -1.59% 115.99% Mar/13
IQVIA Holdings 164.72 1.79 1.10% -11.05% Mar/13
Dianthus Therapeutics 77.86 -2.46 -3.06% 265.03% Mar/13
Moderna 52.56 -0.83 -1.55% 51.82% Mar/13

Indexes Price Day Year Date
HK50 25479 13.40 0.05% 5.52% Mar/16

Sino Biopharmaceutical Ltd traded at 5.95 this Friday March 13th, decreasing 0.08 or 1.33 percent since the previous trading session. Looking back, over the last four weeks, Sino Biopharmaceutical lost 8.88 percent. Over the last 12 months, its price rose by 68.56 percent. Looking ahead, we forecast Sino Biopharmaceutical Ltd to be priced at 5.72 by the end of this quarter and at 5.07 in one year, according to Trading Economics global macro models projections and analysts expectations.

Sino Biopharmaceutical Limited is an investment holding company principally engaged in the medicine products business. The Company operates through three business segments. The Modernized Chinese Medicines and Chemical Medicines segment is engaged in the manufacture, sales and distribution of modernized Chinese medicine products and western medicine products. The Investment segment is engaged in long term investments. The Others segment is engaged in the provision of research and development activities and services to third parties, as well as related healthcare and hospital business. The Company is also involved in the property holding, the sales of health food, the manufacture and optometry of optical glasses, as well as the retail and wholesale of optical and auditory products through its subsidiaries.